ECSEL
ECSEL Joint Undertaking, supporting projects of the ENIAC JU, announces the project “EnLight” as the winner of the 2014 Innovation Award at the European Nanoelectronics Forum. EnLight– Energy Efficient and Intelligent Lighting Systems – developed innovative solutions to exploit the full potential of Solid State LED Lighting for energy efficient and intelligent lighting systems, yielding energy savings that go far beyond what is possible by simple retrofit lighting applications.
On behalf of the 27-partner strong consortium from five European countries, EnLight project coordinator Frank van Tuijl of Philips Lighting took receipt of the annual “ENIAC Innovation Award”. The total cost of the project - € 41.3 million - was supported in part by funding from the ENIAC Joint Undertaking and by contributions from each of the respective National agencies.
Dr. Andreas Wild, Executive Director of ECSEL Joint Undertaking (the organization succeeding ENIAC JU) said: “The project EnLight demonstrated once more that the semiconductor technology is at the core of the European industrial competence, fully delivering on its promise when leading actors innovate along the full value chain, from device suppliers, to software and integration specialists, and to system developers.” Dr. Yves Gigase, ECSEL Head of Operations, recalled that the award recognises the high impact of on the lighting industry: the three representative pilots confirmed equal or even improved user comfort while saving from 45% up to70% energy, well exceeding the initial target of 40% energy reduction, compared to state-of-the-art LED retrofit lamps. In addition, a Power Grid Effects Demonstrator showed that the solutions are compliant with the reference norms, enabling the path to industrial deployment.
The “EnLight” consortium : Applied Micro Electronics «AME» B.V., BJB GmbH & Co.KG, Commissariat à l’énergie atomique et aux énergies alternatives, Eagle Vision Systems B.V., Enel Distribuzione SpA, Fico B.V./Besi, Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., Helvar Oy Ab, Infineon Technologies AG, I-NRG B.V., Insta Elektro GmbH, Legrand France SA, Nederlandse Organisatie voor Toegepastnatuurwetenschappelijk Onderzoek, NXP Semiconductors France SAS, NXP Semiconductors Germany GmbH, OSRAM GmbH, Philips Electronics Nederland B.V., Philips Lighting B.V., PKC Electronics, Plugwise B.V., Rheinisch-Westfälische Technische Hochschule Aachen, Technische Universiteit Delft, Technische Universiteit Eindhoven, There Corporation Ltd., Università degli Studi di Perugia, Valopaa Oy, Valtion Teknillinen Tutkimuskeskus.
Participating States: Finland, France, Germany, Italy, The Netherlands
Further information about this project can be found at:
www.eniac.eu/web/downloads/projectprofiles/call3_enlight.pdf
www.enlight-project.eu
About ENIAC : The ENIAC Joint Undertaking (JU) is a public-private partnership on nanoelectronics bringing together the ENIAC member States, the European Union, and AENEAS (an association representing European R&D actors in this field). The value of the R&D activities generated through this partnership is estimated to total 3 B€ and is supported through grants from the European Union Framework Programme 7, as well as from the ENIAC Member States. Since July 2014, support of the projects launched under ENIAC has been taken up by the ECSEL Joint Undertaking. See www.ecsel.eu for further information.
Contact:
Alun Foster, ECSEL Head of Plans and Dissemination
Tel:
(+32-2)-221-81-22
Email: alun.foster@ecsel.europa.eu
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 09:15:00 CEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release
Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release
New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum